Equity · Healthcare
RPRX
NASDAQRoyalty Pharma (RPRX)
The line runs 61 USD on 24 August through 57.14 USD on 2 October, on a scale from 55.0 to 65.0. Days the market did not trade hold the previous close, flat.
- Market cap
- 25.6B USD
- P/E (TTM)
- 37.4
- Revenue, year to Dec 2025
- 2.4B USD
- EPS, diluted, year to Dec 2025
- 1.78 USD
- 52-week range
- 35 USD – 64 USD
- Avg volume
- 200.5K
as of Oct 2, 2026
Have Royalty Pharma (RPRX) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Royalty Pharma insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 5 Nov 2025, show no open-market purchase.
Form 4, 90 days to 22 Nov 2026, newest reported trade 17 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 17 Nov 2026 | Coyne Terrance P.EVP & CFO | Sell | 24,586 | 1.7M USD |
| 17 Nov 2026 | Hite ChristopherEVP & Chairman, Partnering | Sell | 100,000 | 6.8M USD |
| 16 Nov 2026 | Coyne Terrance P.EVP & CFO | Sell | 232,536 | 16.0M USD |
| 16 Nov 2026 | Urist MarshallEVP, Research & Investments | Sell | 25,000 | 1.7M USD |
| 05 Oct 2026 | Urist MarshallEVP, Research & Investments | Sell | 4,126 | 236K USD |
| 28 Sep 2026 | Urist MarshallEVP, Research & Investments | Sell | 4,126 | 239K USD |
| 22 Sep 2026 | Hite ChristopherEVP & Chairman, Partnering | Sell | 100,000 | 5.9M USD |
| Sold | 7 open-market sales | 490,374 | $32.57M |
7 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 06 Nov 2026 | Coyne Terrance P.EVP & CFO | Other | 250,000 | |
| 06 Nov 2026 | Urist MarshallEVP, Research & Investments | Other | 150,000 | |
| 04 Nov 2026 | Coyne Terrance P.EVP & CFO | Award | 7,122 | |
| 04 Nov 2026 | Hite ChristopherEVP & Chairman, Partnering | Award | 7,122 | |
| 04 Nov 2026 | Legorreta Pablo G.CEO, Chairman of the Board | Award | 42,209 | |
| 04 Nov 2026 | Urist MarshallEVP, Research & Investments | Award | 5,341 | |
| 30 Sep 2026 | Bassler Bonnie LDirector | Award | 642 | 37K USD |
Which funds hold Royalty Pharma (RPRX)?
12 of the 45 institutional funds we track reported a Royalty Pharma position for the quarter ended 30 Sep 2026 — a combined 710.3M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| AQR Capital Management | Held (±25%) | 3,709,286 | 215.2M USD | −13.8% |
| Two Sigma Investments | Held (±25%) | 2,213,896 | 129.2M USD | −24.2% |
| Citadel Advisors | Held (±25%) | 1,471,044 | 85.9M USD | +8.6% |
| Point72 Asset Management | Added | 1,123,256 | 65.6M USD | +954.2% |
| Balyasny Asset Management | New position | 678,741 | 39.6M USD | |
| Marshall Wace | Trimmed | 631,700 | 36.9M USD | −74.2% |
| Renaissance Technologies | Trimmed | 591,100 | 34.5M USD | −69.5% |
| Tudor Investment Corp | Held (±25%) | 510,736 | 29.8M USD | −16.4% |
| Bridgewater Associates | Added | 474,521 | 27.7M USD | +116.0% |
| D. E. Shaw & Co. | Held (±25%) | 413,898 | 24.2M USD | −21.2% |
Showing the 10 largest of 12 reported positions. The figures above count all of them.
What has been filed or recorded for Royalty Pharma (RPRX)?
The filings we hold for Royalty Pharma, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 28 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 28 Oct 2026 | Fails to deliver | Shares failed to deliver | 54 shares | 4K USD notional · <0.001% of shares out |
| 26 Oct 2026 | Fails to deliver | Shares failed to deliver | 21,370 shares | 1.4M USD notional · 0.005% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 23,760 shares | 1.3M USD notional · 0.005% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.32 USD | Revenue $690M |
| 30 Sep 2026 | Financials | Total assets | 19.5B USD | at period end |
| 30 Sep 2026 | Financials | Total equity incl. minority interest | 9.8B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.04 USD | Revenue $674M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.67 USD | Revenue $631M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 1.78 USD | Revenue $2.38B |
| 31 Dec 2025 | Financials | Revenue | 2.4B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 770.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 1.78 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.66 USD | Revenue $609M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.07 USD | Revenue $579M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.55 USD | Revenue $568M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 1.91 USD | Revenue $2.26B |
What do people ask about Royalty Pharma (RPRX)?
What did Royalty Pharma shares close at?57.14
Royalty Pharma closed at 57.14 USD on 2 Oct 2026, down 0.86% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Royalty Pharma’s market cap?25.6B
Royalty Pharma is worth 25.6B USD by market value as of 2 Oct 2026, which is the share price times the shares on issue from its SEC filings.
What is Royalty Pharma’s P/E ratio?37.4
Royalty Pharma has a price-to-earnings ratio of 37.4, as of 2 Oct 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Royalty Pharma’s revenue?2.4B
Royalty Pharma reported revenue of 2.4B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Royalty Pharma insiders bought or sold shares recently?7 sales
In the 90 days to 22 Nov 2026, Royalty Pharma insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 5 Nov 2025, show no open-market purchase. A further 7 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Royalty Pharma?12 of 45
12 of the 45 funds we track reported a Royalty Pharma position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Two Sigma Investments and Citadel Advisors. See Funds
When did Royalty Pharma last report earnings?0.32
Royalty Pharma last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.32 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words